File Download
  Links for fulltext
     (May Require Subscription)

Article: Inhaled fluticasone in bronchiectasis: A 12 month study

TitleInhaled fluticasone in bronchiectasis: A 12 month study
Authors
Issue Date2005
PublisherB M J Publishing Group. The Journal's web site is located at http://thorax.bmjjournals.com/
Citation
Thorax, 2005, v. 60 n. 3, p. 239-243 How to Cite?
Abstract
Background: The clinical efficacy of inhaled corticosteroid (ICS) treatment has not been evaluated in bronchiectasis, despite the presence of chronic airway inflammation. Methods: After three consecutive weekly visits, 86 patients were randomised to receive either fluticasone 500 μ9 twice daily (n = 43, 23F, mean (SD) age 57.7 (14.4) years) or matched placebo (n = 43, 34F, 59.2 (14.2) years) and reviewed regularly for 52 weeks in a double blind fashion. Results: 35 and 38 patients in the fluticasone and placebo groups completed the study. Significantly more patients on ICS than on placebo showed improvement in 24 hour sputum volume (OR 2.5, 95% CI 1.1 to 6.0, p = 0.03) but not in exacerbation frequency, forced expiratory volume in 1 second, forced vital capacity, or sputum purulence score. Significantly more patients with Pseudomonas aeruginosa infection receiving fluticasone showed improvement in 24 hour sputum volume (OR 13.5, 95% CI 1.8 to 100.2, p = 0.03) and exacerbation frequency (OR 13.3, 95% CI 1.8 to 100.2, p = 0.01 ) than those given placebo. Logistic regression models revealed a significantly better response in sputum volume with fluticasone treatment than with placebo among subgroups of patients with 24 hour sputum volume <30 ml (p = 0.04), exacerbation frequency ≤2/year (p = 0.04), and sputum purulence score >5 (p = 0.03). Conclusions: ICS treatment is beneficial to patients with bronchiectasis, particularly those with P aerurginosa infection.
Persistent Identifierhttp://hdl.handle.net/10722/42019
ISSN
2013 Impact Factor: 8.562
PubMed Central ID
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTsang, KWen_HK
dc.contributor.authorTan, KCen_HK
dc.contributor.authorHo, PLen_HK
dc.contributor.authorOoi, GCen_HK
dc.contributor.authorHo, JCen_HK
dc.contributor.authorMak, Jen_HK
dc.contributor.authorTipoe, GLen_HK
dc.contributor.authorKo, Cen_HK
dc.contributor.authorYan, Cen_HK
dc.contributor.authorLam, WKen_HK
dc.contributor.authorChanYeung, Men_HK
dc.date.accessioned2007-01-08T02:27:02Z-
dc.date.available2007-01-08T02:27:02Z-
dc.date.issued2005en_HK
dc.identifier.citationThorax, 2005, v. 60 n. 3, p. 239-243en_HK
dc.identifier.issn0040-6376en_HK
dc.identifier.urihttp://hdl.handle.net/10722/42019-
dc.description.abstractBackground: The clinical efficacy of inhaled corticosteroid (ICS) treatment has not been evaluated in bronchiectasis, despite the presence of chronic airway inflammation. Methods: After three consecutive weekly visits, 86 patients were randomised to receive either fluticasone 500 μ9 twice daily (n = 43, 23F, mean (SD) age 57.7 (14.4) years) or matched placebo (n = 43, 34F, 59.2 (14.2) years) and reviewed regularly for 52 weeks in a double blind fashion. Results: 35 and 38 patients in the fluticasone and placebo groups completed the study. Significantly more patients on ICS than on placebo showed improvement in 24 hour sputum volume (OR 2.5, 95% CI 1.1 to 6.0, p = 0.03) but not in exacerbation frequency, forced expiratory volume in 1 second, forced vital capacity, or sputum purulence score. Significantly more patients with Pseudomonas aeruginosa infection receiving fluticasone showed improvement in 24 hour sputum volume (OR 13.5, 95% CI 1.8 to 100.2, p = 0.03) and exacerbation frequency (OR 13.3, 95% CI 1.8 to 100.2, p = 0.01 ) than those given placebo. Logistic regression models revealed a significantly better response in sputum volume with fluticasone treatment than with placebo among subgroups of patients with 24 hour sputum volume <30 ml (p = 0.04), exacerbation frequency ≤2/year (p = 0.04), and sputum purulence score >5 (p = 0.03). Conclusions: ICS treatment is beneficial to patients with bronchiectasis, particularly those with P aerurginosa infection.en_HK
dc.format.extent101963 bytes-
dc.format.extent25088 bytes-
dc.format.extent618083 bytes-
dc.format.extent4522 bytes-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypeapplication/msword-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypetext/plain-
dc.languageengen_HK
dc.publisherB M J Publishing Group. The Journal's web site is located at http://thorax.bmjjournals.com/en_HK
dc.relation.ispartofThoraxen_HK
dc.rightsThorax. Copyright © B M J Publishing Group.en_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject.meshAdministration, inhalationen_HK
dc.subject.meshAndrostadienes - administration & dosageen_HK
dc.subject.meshBronchiectasis - drug therapyen_HK
dc.subject.meshForced expiratory volume - physiologyen_HK
dc.subject.meshVital capacityen_HK
dc.titleInhaled fluticasone in bronchiectasis: A 12 month studyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0040-6376&volume=60&issue=3&spage=239&epage=243&date=2005&atitle=Inhaled+fluticasone+in+bronchiectasis:+a+12+month+studyen_HK
dc.identifier.emailTan, KC:kcbtan@hku.hken_HK
dc.identifier.emailHo, PL:plho@hkucc.hku.hken_HK
dc.identifier.emailHo, JC:jhocm@hku.hken_HK
dc.identifier.emailMak, J:judymak@hku.hken_HK
dc.identifier.emailTipoe, GL:tgeorge@hkucc.hku.hken_HK
dc.identifier.authorityTan, KC=rp00402en_HK
dc.identifier.authorityHo, PL=rp00406en_HK
dc.identifier.authorityHo, JC=rp00258en_HK
dc.identifier.authorityMak, J=rp00352en_HK
dc.identifier.authorityTipoe, GL=rp00371en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.doi10.1136/thx.2002.003236en_HK
dc.identifier.pmid15741443en_HK
dc.identifier.pmcidPMC1747352-
dc.identifier.scopuseid_2-s2.0-20144377363en_HK
dc.identifier.hkuros117978-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-20144377363&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume60en_HK
dc.identifier.issue3en_HK
dc.identifier.spage239en_HK
dc.identifier.epage243en_HK
dc.identifier.isiWOS:000227470700016-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridTsang, KW=7201555024en_HK
dc.identifier.scopusauthoridTan, KC=8082703100en_HK
dc.identifier.scopusauthoridHo, PL=7402211363en_HK
dc.identifier.scopusauthoridOoi, GC=7006176119en_HK
dc.identifier.scopusauthoridHo, JC=7402649981en_HK
dc.identifier.scopusauthoridMak, J=7103323094en_HK
dc.identifier.scopusauthoridTipoe, GL=7003550610en_HK
dc.identifier.scopusauthoridKo, C=8728540600en_HK
dc.identifier.scopusauthoridYan, C=8728540500en_HK
dc.identifier.scopusauthoridLam, WK=7203021937en_HK
dc.identifier.scopusauthoridChanYeung, M=54790582200en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats